Surviving, Sustaining & Succeeding in the Pursuit of Innovation

by Lilith Anderson.
Last Updated by Lilith Anderson.

Public Categorized as Public.

Tagged with audio, biotechnology, drug development, key concepts, keynote speaker, pharmaceuticals and strategies.

The innovation deficit that has plagued the global pharmaceutical industry for at least the last ten years has finally extracted its toll: between 2008 and 2012 more than $218 billion of branded pharmaceutical revenue will be lost to generics. The industry has nothing visible in its late-stage pipelines to replace a sales loss of this magnitude. All big pharmaceutical companies are now preparing for the inevitable by aggressively downsizing across all functions, including the once sacred R&D. Big Pharma is, at least for the interim, becoming Much Smaller Pharma. Despite this dismal prognosis, the pending demise of Big Pharma will, in the future, be regarded as a positive development. New business models are an urgent necessity if Pharma is ever to return to its golden years of innovation and growth-and if patients are going to have much needed new therapies.

Listen to the Presentation

You need Adobe Flash to play this media. Get the flash player here

Pointers

The growth and fall of big pharma
Pharma's interim playbook-what pharma has done and failed at
What global health is changing into-pharma's new playbook
The new realities of pharmaceutical IPO's

Download Audio Presentation (54.8 MB) (54.8 MB)
Download PowerPoint Presentation (5 MB) (5 MB) (5 MB)

Keynote Speaker

Edward C. Saltzman
Founder and President, Defined Health

Edward C. Saltzman
Salztman is founder and President of Defined Health, a leading consultancy in business development and disease area strategy for the pharmaceutical industry. Since its founding in 1983, Defined Health has completed thousands of opportunity assessments and commercial forecasts of development stage projects for hundreds of corporate clients across the Big Pharma, Biotechnology and Specialty Pharma complex. Defined Health's length and breadth of experience in evaluating pipeline opportunities provides the firm with a unique and often unconventional spotlight on strategic issues confronting the industry, particularly with respect to the quality of the development pipeline and its implications for sustainability of established and evolving business models.